Back | Next |
home / stock / ifrx / ifrx message board
Subject | By | Source | When |
---|---|---|---|
4.40s 4.50s could be stronge support | peterus | investorshub | 04/12/2023 1:25:57 PM |
agree | peterus | investorshub | 04/12/2023 10:54:21 AM |
Ok today we will see $4 first step | the_stockoracle | investorshub | 04/12/2023 10:53:57 AM |
lol will never see $2 maybe in your | peterus | investorshub | 04/12/2023 10:33:08 AM |
Lol ?? youre delusional major diluting down to $2 | the_stockoracle | investorshub | 04/12/2023 10:23:05 AM |
I will be loading on the 10 million | enthalpy | investorshub | 04/12/2023 2:38:53 AM |
New highs by EOW??? | RobP33 | investorshub | 04/11/2023 11:32:40 PM |
Only had 2 minutes missed the 4.60 buy. | enthalpy | investorshub | 04/11/2023 8:31:08 PM |
We will see i have 1/3 of position | enthalpy | investorshub | 04/11/2023 6:27:26 PM |
yup i think you could be right | peterus | investorshub | 04/11/2023 6:13:50 PM |
Fibonacci 38% pull back is $5.00 and 62% | enthalpy | investorshub | 04/11/2023 6:12:39 PM |
fliped out side line ... waiting | peterus | investorshub | 04/11/2023 6:06:38 PM |
Waiting for $4.00. Enjoy the ride down. | enthalpy | investorshub | 04/11/2023 5:56:20 PM |
Picked up 1/4 at 5.00. Waiting for rest | enthalpy | investorshub | 04/10/2023 7:45:00 PM |
Guys man why didnt you take your profits | the_stockoracle | investorshub | 04/10/2023 6:47:06 PM |
https://stockcharts.com/h-sc/ui?s=ifrx&p=D&yr=0&mn=6&dy=0&id=p38090673899 htt | surf1944 | investorshub | 04/10/2023 3:01:12 PM |
$IFRX should see minimum 10-11 this week. | dinogreeves | investorshub | 04/10/2023 5:32:26 AM |
Good job. Im waiting for rsi to cool | enthalpy | investorshub | 04/10/2023 4:19:34 AM |
Better believe it is going to happen. | dinogreeves | investorshub | 04/09/2023 11:32:26 PM |
$IFRX is going to leap fast forward to | dinogreeves | investorshub | 04/08/2023 4:11:27 AM |
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...